Economic Evaluation of anti-epileptic Medicines for Autistic Children with Epilepsy.

Autism Children Cost-effectiveness Epilepsy Family impacts Healthcare expenditure

Journal

Journal of autism and developmental disorders
ISSN: 1573-3432
Titre abrégé: J Autism Dev Disord
Pays: United States
ID NLM: 7904301

Informations de publication

Date de publication:
04 May 2023
Historique:
accepted: 17 02 2023
medline: 5 5 2023
pubmed: 5 5 2023
entrez: 4 5 2023
Statut: aheadofprint

Résumé

We examine the cost-effectiveness of treating epilepsy with anti-epileptic medicines in autistic children, looking at impacts on healthcare providers (in England, Ireland, Italy and Spain) and children's families (in Ireland). We find carbamazepine to be the most cost-effective drug to try first in children with newly diagnosed focal seizures. For England and Spain, oxcarbazepine is the most cost-effective treatment when taken as additional treatment for those children whose response to monotherapy is suboptimal. In Ireland and Italy, gabapentin is the most cost-effective option. Our additional scenario analysis presents the aggregate cost to families with autistic children who are being treated for epilepsy: this cost is considerably higher than healthcare provider expenditure.

Identifiants

pubmed: 37142904
doi: 10.1007/s10803-023-05941-8
pii: 10.1007/s10803-023-05941-8
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Commission européenne Office Européen de Lutte Antifraude
ID : n/a

Informations de copyright

© 2023. The Author(s).

Références

Allers, K., Essue, B. M., Hackett, M. L., Muhunthan, J., Anderson, C. S., Pickles, K., Scheibe, F., & Jan, S. (2015). The economic impact of epilepsy: a systematic review. BMC neurology, 15, 245. https://doi.org/10.1186/s12883-015-0494-y
doi: 10.1186/s12883-015-0494-y pubmed: 26607561 pmcid: 4660784
Almathami, H., Win, K. T., & Vlahu-Gjorgievska, E. (2020). Barriers and facilitators that influence Telemedicine-Based, Real-Time, Online Consultation at Patients’ Homes: systematic literature review. Journal of medical Internet research, 22(2), e16407. https://doi.org/10.2196/16407
doi: 10.2196/16407 pubmed: 32130131 pmcid: 7059083
Andronis, L., Barton, P., & Bryan, S. (2009). Sensitivity analysis in economic evaluation: an audit of NICE current practice and a review of its use and value in decision-making. Health technology assessment (Winchester England), 13(29), iii–61. https://doi.org/10.3310/hta13290
doi: 10.3310/hta13290 pubmed: 19500484
Argumosa, A., & Herranz, J. L. (2004). Childhood epilepsy: a critical review of cost-of-illness studies. Epileptic disorders: international epilepsy journal with videotape, 6(1), 31–40.
pubmed: 15075066
Autistica (2022). Make the most of a telephone health appointment. Retrieved October 15 h 2021 from https://www.autistica.org.uk/what-is-autism/coronavirus/make-the-most-of-a-telephone-appointment
Barrett, B., Byford, S., Sharac, J., Hudry, K., Leadbitter, K., Temple, K., Aldred, C., Slonims, V., Green, J., & PACT Consortium. (2012). Service and wider societal costs of very young children with autism in the UK. Journal of autism and developmental disorders, 42(5), 797–804. https://doi.org/10.1007/s10803-011-1306-x
doi: 10.1007/s10803-011-1306-x pubmed: 22089166
Besag, F. M. (2017). Epilepsy in patients with autism: Links, risks and treatment challenges. Neuropsychiatric Disease and Treatment, 14, 1–10. https://doi.org/10.2147/NDT.S120509
Buescher, A. V., Cidav, Z., Knapp, M., & Mandell, D. S. (2014). Costs of autism spectrum disorders in the United Kingdom and the United States. JAMA pediatrics, 168(8), 721–728. https://doi.org/10.1001/jamapediatrics.2014.210
doi: 10.1001/jamapediatrics.2014.210 pubmed: 24911948
Curtis, L., & Burns, A. (2015). Unit costs of health and social care. Canterbury: Personal Social Services Research Unit. Retrieved October 15 h 2021, from https://www.pssru.ac.uk/project-pages/unit-costs/unit-costs-2015/
Dillenburger, K., Jordan, J. A., McKerr, L., & Keenan, M. (2015). The Millennium child with autism: early childhood trajectories for health, education and economic wellbeing. Developmental neurorehabilitation, 18(1), 37–46. https://doi.org/10.3109/17518423.2014.964378
doi: 10.3109/17518423.2014.964378 pubmed: 25289682
Drummond, M. F., Sculpher, M. J., Claxton, K., Stoddart, G. L., & Torrance, G. W. (2005). Methods for the economic evaluation of Health Care Programmes. Oxford: Oxford University Press.
El Achkar, C. M., & Spence, S. J. (2015). Clinical characteristics of children and young adults with co-occurring autism spectrum disorder and epilepsy. Epilepsy & behavior: E&B, 47, 183–190. https://doi.org/10.1016/j.yebeh.2014.12.022
doi: 10.1016/j.yebeh.2014.12.022
Fleming, M., Fitton, C. A., Steiner, M. F. C., McLay, J. S., Clark, D., King, A., Mackay, D. F., & Pell, J. P. (2019). Educational and health outcomes of children and adolescents receiving antiepileptic medication: Scotland-wide record linkage study of 766 244 schoolchildren. BMC Public Health, 19(1), 595. https://doi.org/10.1186/s12889-019-6888-9
Frew, E. J., Sandercock, J., Whitehouse, W. P., & Bryan, S. (2007). The cost-effectiveness of newer drugs as add-on therapy for children with focal epilepsies. Seizure, 16(2), 99–112. https://doi.org/10.1016/j.seizure.2006.10.017
doi: 10.1016/j.seizure.2006.10.017 pubmed: 17161630
Hawkins, N., Epstein, D., Drummond, M., Wilby, J., Kainth, A., Chadwick, D., & Sculpher, M. (2005). Assessing the cost-effectiveness of new pharmaceuticals in epilepsy in adults: the results of a probabilistic decision model. Medical decision making: an international journal of the Society for Medical Decision Making, 25(5), 493–510. https://doi.org/10.1177/0272989X05280559
doi: 10.1177/0272989X05280559 pubmed: 16160206
Health Information and Quality Authority (HIQA). Guidelines for the economic evaluation of health technologies in Ireland 2020. https://www.hiqa.ie/reports-and-publications/health-technology-assessment/guidelines-economic-evaluation-health
Health Services Executive (HSE). (2021). Hospital charges. Retrieved October 15, 2021, from https://www.hse.ie/eng/about/who/acute-hospitals-division/patient-care/hospital-charges/
Hirfanoglu, T., Serdaroglu, A., Cansu, A., Soysal, A. S., Derle, E., & Gucuyener, K. (2009). Do knowledge of, perception of, and attitudes toward epilepsy affect the quality of life of Turkish children with epilepsy and their parents? Epilepsy & Behavior: E&B, 14(1), 71–77. https://doi.org/10.1016/j.yebeh.2008.08.011
Hirvikoski, T., Mittendorfer-Rutz, E., Boman, M., Larsson, H., Lichtenstein, P., & Bölte, S. (2016). Premature mortality in autism spectrum disorder. The British journal of psychiatry: the journal of mental science, 208(3), 232–238. https://doi.org/10.1192/bjp.bp.114.160192 .
doi: 10.1192/bjp.bp.114.160192 pubmed: 26541693
Hunter, R. M., Reilly, C., Atkinson, P., Das, K. B., Gillberg, C., Chin, R. F., Scott, R. C., Neville, B. G., & Morris, S. (2015). The health, education, and social care costs of school-aged children with active epilepsy: a population-based study. Epilepsia, 56(7), 1056–1064. https://doi.org/10.1111/epi.13015
doi: 10.1111/epi.13015 pubmed: 26040629
Hussain, S. A., Ortendahl, J. D., Bentley, T., Harmon, A. L., Gupta, S., Begley, C. E., Khilfeh, I., & Knoth, R. L. (2020). The economic burden of caregiving in epilepsy: an estimate based on a survey of US caregivers. Epilepsia, 61(2), 319–329. https://doi.org/10.1111/epi.16429
doi: 10.1111/epi.16429 pubmed: 31953846
Jacoby, A., & Austin, J. K. (2007). Social stigma for adults and children with epilepsy. Epilepsia, 48(Suppl 9), 6–9. https://doi.org/10.1111/j.1528-1167.2007.01391.x
Järbrink, K., McCrone, P., Fombonne, E., Zandén, H., & Knapp, M. (2000) Cost-impact of young adults with high-functioning autistic spectrum disorder. Research in Developmental Disabilities 28(1), 94–104.
Jennum, P., Gyllenborg, J., & Kjellberg, J. (2011). The social and economic consequences of epilepsy: a controlled national study. Epilepsia, 52(5), 949–956. https://doi.org/10.1111/j.1528-1167.2010.02946.x
doi: 10.1111/j.1528-1167.2010.02946.x pubmed: 21275976
Jennum, P., Pickering, L., Christensen, J., Ibsen, R., & Kjellberg, J. (2016). Welfare cost of childhood- and adolescent-onset epilepsy: a controlled national study. Epilepsy & behavior: E&B, 61, 72–77. https://doi.org/10.1016/j.yebeh.2016.04.044
doi: 10.1016/j.yebeh.2016.04.044
Jennum, P., Christensen, J., Ibsen, R., & Kjellberg, J. (2016). Long-term socioeconomic consequences and health care costs of childhood and adolescent-onset epilepsy. Epilepsia, 57(7), 1078–1085. https://doi.org/10.1111/epi.13421 .
doi: 10.1111/epi.13421 pubmed: 27321903
Knapp, M., Snell, T., Healey, A., Guglani, S., Evans-Lacko, S., Fernandez, J. L., Meltzer, H., & Ford, T. (2015). How do child and adolescent mental health problems influence public sector costs? Interindividual variations in a nationally representative British sample. Journal of Child Psychology and Psychiatry, and Allied Disciplines, 56(6), 667–676. https://doi.org/10.1111/jcpp.12327
Lavelle, T. A., D’Cruz, B. N., Mohit, B., Ungar, W. J., Prosser, L. A., Tsiplova, K., Vera-Llonch, M., & Lin, P. J. (2019). Family Spillover Effects in Pediatric cost-utility analyses. Applied health economics and health policy, 17(2), 163–174. https://doi.org/10.1007/s40258-018-0436-0
doi: 10.1007/s40258-018-0436-0 pubmed: 30350218
Lee, D., Gladwell, D., Batty, A. J., Brereton, N., & Tate, E. (2013). The cost effectiveness of licensed oromucosal midazolam (Buccolam(®)) for the treatment of children experiencing acute epileptic seizures: an approach when trial evidence is limited. Paediatric drugs, 15(2), 151–162. https://doi.org/10.1007/s40272-013-0009-5
doi: 10.1007/s40272-013-0009-5 pubmed: 23512129
Lee, D. C., Gladwell, D., Hatswell, A. J., Porter, J., Brereton, N., Tate, E., & Saunders, A. L. (2014). A comparison of the cost-effectiveness of treatment of prolonged acute convulsive epileptic seizures in children across Europe. Health economics review, 4, 6. https://doi.org/10.1186/s13561-014-0006-6
doi: 10.1186/s13561-014-0006-6 pubmed: 24949280 pmcid: 4052771
Liu, X., Sun, X., Sun, C., Zou, M., Chen, Y., Huang, J., Wu, L., & Chen, W. X. (2022). Prevalence of epilepsy in autism spectrum disorders: a systematic review and meta-analysis. Autism, 26(1), 33–50.
doi: 10.1177/13623613211045029 pubmed: 34510916
MIMS Ireland (2019). MPI Media Ltd., Dublin, Ireland. Retrieved October 15 h 2021 from https://www.mims.ie/
National Clinical Guideline Centre (UK). (2012). The epilepsies: The diagnosis and management of the epilepsies in adults and children in primary and secondary care. Royal College of Physicians (UK).
NICE (2021). Epilepsies: diagnosis and management. Retrieved October 15 h 2021 from https://www.nice.org.uk/guidance/cg137
NICE (2023). Glossary. https://www.nice.org.uk/glossary
Perucca, E., Battino, D., & Tomson, T. (2014). Gender issues in antiepileptic drug treatment. Neurobiology of disease 72 Pt B, 217–223. https://doi.org/10.1016/j.nbd.2014.05.011
Samba Reddy, D. (2017). Sex differences in the anticonvulsant activity of neurosteroids. Journal of neuroscience research, 95(1–2), 661–670. https://doi.org/10.1002/jnr.23853
Snell, T., Knapp, M., Healey, A., Guglani, S., Evans-Lacko, S., Fernandez, J. L., Meltzer, H., & Ford, T. (2013). Economic impact of childhood psychiatric disorder on public sector services in Britain: estimates from national survey data. Journal of child psychology and psychiatry, and allied disciplines, 54(9), 977–985. https://doi.org/10.1111/jcpp.12055
Whitehead, S. J., & Ali, S. (2010). Health outcomes in economic evaluation: the QALY and utilities. British medical bulletin, 96, 5–21.
doi: 10.1093/bmb/ldq033 pubmed: 21037243
Widjaja, E., Guttmann, A., Tomlinson, G., Snead, O. C. 3rd, & Sander, B. (2021). Economic burden of epilepsy in children: a population-based matched cohort study in Canada. Epilepsia, 62(1), 152–162. https://doi.org/10.1111/epi.16775
Wijnen, B., van Mastrigt, G., Evers, S., Gershuni, O., Lambrechts, D., Majoie, M., Postulart, D., Aldenkamp, B., & de Kinderen, R. (2017). A systematic review of economic evaluations of treatments for patients with epilepsy. Epilepsia, 58(5), 706–726. https://doi.org/10.1111/epi.13655
doi: 10.1111/epi.13655 pubmed: 28098939
Zack, M. M., & Kobau, R. (2017). National and state estimates of the numbers of adults and children with active epilepsy - United States, 2015. MMWR. Morbidity and Mortality Weekly Report, 66(31), 821–825. https://doi.org/10.15585/mmwr.mm6631a1

Auteurs

Michela Tinelli M (M)

Care Policy and Evaluation Centre, London School of Economics and Political Science, London, UK. m.tinelli@lse.ac.uk.

Aine Roddy (A)

Care Policy and Evaluation Centre, London School of Economics and Political Science, London, UK.
Atlantic Technological University, Sligo, Ireland.

Martin Knapp (M)

Care Policy and Evaluation Centre, London School of Economics and Political Science, London, UK.

Celso Arango (C)

Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, School of Medicine, Hospital General Universitario Gregorio Marañón, Universidad Complutense, CIBERSAM, IiSGM, Madrid, Spain.

Maria Andreina Mendez (MA)

Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, School of Medicine, Hospital General Universitario Gregorio Marañón, Universidad Complutense, CIBERSAM, IiSGM, Madrid, Spain.

James Cusack (J)

Autistica, London, UK.

Declan Murphy (D)

Kings College London, London, UK.

Roberto Canitano (R)

azienda - Azienda ospedaliero-universitaria Senese, Siena, Italy.

Bethany Oakley (B)

Kings College London, London, UK.

Vinciane Quoidbach (V)

European Brain Council, Bruxelles, Belgium.

Classifications MeSH